ISIS Pharmaceuticals Given Average Recommendation of “Hold” by Analysts … – Dakota Financial News

ISIS Pharmaceuticals Given Average Recommendation of “Hold” by Analysts …Dakota Financial NewsThe Firm is focused to find and develop antisense drugs. The antisense drugs are accustomed to take care of a range of diseases, including cardiovascular, metabolic, acute and rare diseases. ISIS APOCIII is a drug demonstrated to to treat patients with …and more »

Read More

PharmaSphere: Emerging Biotechnologies – Antisense RNAi Therapeutics Market … – GlobeNewswire (press release)

PharmaSphere: Emerging Biotechnologies – Antisense RNAi Therapeutics Market …GlobeNewswire (press release)Albany – NY, Oct. 21, 2015 (GLOBE NEWSWIRE) — “PharmaSphere: Emerging Biotechnologies Antisense RNAi Therapeutics Market Analysis” report is an essential source of information and analysis on the RNA interference (RNAi) therapy field.and more »

Read More

X-Chromosome Silencing Depends on Antisense RNA – Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology NewsX-Chromosome Silencing Depends on Antisense RNAGenetic Engineering & Biotechnology NewsThink of the silencing of the X chromosome as a construction project. Then, imagine you hear the beeping of heavy machinery operating in reverse. That’s the sound of the Xist gene being transcribed in the backwards, or antisense, direction. The Xist …Female cells use RNA to turn off X chromosomeFuturity: Research NewsX-citing X chromosome discovery could aid research on many sex-linked disordersPhys.Orgall 9 news articles »

Read More

First patients receive doses of antisense drug for Huntington’s disease – News-Medical.net

BBC NewsFirst patients receive doses of antisense drug for Huntington’s diseaseNews-Medical.net’Gene silencing’ drugs, also known as ‘antisense’ drugs, are designed to reduce production of a chosen protein by attaching to the mRNA ‘message molecule’ that’s made whenever a gene is activated. ISIS-HTTRx targets the huntingtin message molecule, …Liftoff: First humans treated with gene silencing drugs for HD!HDBuzzFirst human trial for innovative new drug in development to treat Huntington’s …HealthCanal.com (press release) (blog)all 8 news articles »

Read More

Isarna Therapeutics and Autotelic Signed Asset Sale and Purchase Agreement for … – Business Wire (press release)

Isarna Therapeutics and Autotelic Signed Asset Sale and Purchase Agreement for …Business Wire (press release)MUNICH & FOUNTAIN VALLEY, Calif.–(BUSINESS WIRE)–Isarna Therapeutics, the leader in transforming growth factor beta (TGF-β) isoform targeted antisense therapeutics, and Autotelic Inc., a specialist in therapeutic drug monitoring and development, …and more »

Read More

Can a ‘sense’ DNA drug reverse antisense drug to treat blood clots and prevent … – EurekAlert (press release)

EurekAlert (press release)Can a ‘sense’ DNA drug reverse antisense drug to treat blood clots and prevent …EurekAlert (press release)New Rochelle, NY, October, 13, 2015–Researchers from Isis Pharmaceuticals (Carlsbad, CA) and Prysis Biotechnologies (Pudong, Shanghai, China) have demonstrated proof-of-concept for using a sense oligonucleotide to undo the effects of an antisense …

Read More

Wave Life Sciences Files for IPO – 24/7 Wall St.

24/7 Wall St.Wave Life Sciences Files for IPO24/7 Wall St…. on the market or in development by others. This platform can be used to design therapies that utilize any of the major molecular mechanisms employed by nucleic acid therapeutics, including antisense, ribonucleic acid interference exon skipping and …

Read More

Antisense and RNAi Therapeutics Market 2015 to grow at a CAGR of 26.79% by 2019 – Medgadget.com (blog)

Medgadget.com (blog)Antisense and RNAi Therapeutics Market 2015 to grow at a CAGR of 26.79% by 2019Medgadget.com (blog)Antisense-and-RNAi-Therapeutics-Market-2015 The Report “Global Antisense and RNAi Therapeutics Market 2015-2019” has been prepared on the basis of an in-depth Antisense and RNAi Therapeutics Market 2015 analysis with inputs from team of …and more »

Read More

BioMarin Receives Favorable Ruling in the Use of Exon 51 Antisense … – GlobeNewswire (press release)

TheStreet.comBioMarin Receives Favorable Ruling in the Use of Exon 51 Antisense …GlobeNewswire (press release)SAN RAFAEL, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Patent Trial and Appeal Board (PTAB) issued a decision in favor of BioMarin’s claims to the use of exon 51 antisense …Sarepta on losing end of exon 51 skipping patent ruling in favor of BioMarin …Seeking Alphaall 26 news articles »

Read More

PharmaSphere: Emerging Biotechnologies – Antisense RNAi Therapeutics Market … – PR Newswire (press release)

PharmaSphere: Emerging Biotechnologies – Antisense RNAi Therapeutics Market …PR Newswire (press release)GlobalData’s “PharmaSphere: Emerging Biotechnologies – Antisense RNAi Therapeutics Market Analysis” report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, …and more »

Read More

ISIS Pharmaceuticals Given Consensus Recommendation of “Hold” by Analysts … – The Market Business

ISIS Pharmaceuticals Given Consensus Recommendation of “Hold” by Analysts …The Market BusinessThe antisense drugs are accustomed to take care of a variety of ailments, including cardiovascular, metabolic, severe and rare diseases, including cancer and neurological disorders. ISIS APOCIII is a drug demonstrated to to treat patients with high …ISIS Pharmaceuticals Earns Equal Weight Rating from Analysts at Barclays (ISIS)The LegacyBarclays Initiates Coverage on ISIS Pharmaceuticals (ISIS)WKRB NewsISIS Pharmaceuticals Rating Increased to Hold at Vetr Inc. (ISIS)Mideast Timeall 6 news articles »

Read More

Research and Markets: PharmaSphere: Emerging Biotechnologies – Antisense RNAi … – Business Wire (press release)

Research and Markets: PharmaSphere: Emerging Biotechnologies – Antisense RNAi …Business Wire (press release)”PharmaSphere: Emerging Biotechnologies – Antisense RNAi Therapeutics Market Analysis” report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, corporate …Antisense RNAi Therapeutics Market Emerging Biotechnologies Report Available …PharmiWeb.com (press release)all 7 news articles »

Read More

Antisense RNAi Therapeutics Market Emerging Biotechnologies Report Available … – PharmiWeb.com (press release)

Antisense RNAi Therapeutics Market Emerging Biotechnologies Report Available …PharmiWeb.com (press release)24, 2015 /PRNewswire-iReach/ — The report “PharmaSphere: Emerging Biotechnologies – Antisense RNAi Therapeutics Market Analysis” report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed …and more »

Read More

ISIS Pharmaceuticals Lifted to “Hold” at Vetr Inc. (ISIS) – The Legacy

ISIS Pharmaceuticals Lifted to “Hold” at Vetr Inc. (ISIS)The LegacyThe Company is focused to find and develop antisense drugs. The antisense drugs are accustomed to take care of a range of diseases, including cardiovascular, rare, intense and metabolic diseases, including cancer and neurological disorders. ISIS …Barclays Initiates Coverage on ISIS Pharmaceuticals (ISIS)WKRB Newsall 3 news articles »

Read More

Antisense Inhibitor Lowers High Triglycerides – JAMA: The Journal of the American Medical Association

JAMA: The Journal of the American Medical AssociationAntisense Inhibitor Lowers High TriglyceridesJAMA: The Journal of the American Medical AssociationA recent phase 2 randomized controlled trial reported that short-term treatment with ISIS 304801, a second-generation antisense inhibitor of apolipoprotein C-III (APOC3) synthesis, reduced triglyceride levels in patients with severe or uncontrolled …

Read More

Three “Remarkable” Studies Say Clogged Pores May Cause ALS; Drug Targets ID’d – Bioscience Technology

Bioscience TechnologyThree “Remarkable” Studies Say Clogged Pores May Cause ALS; Drug Targets ID’dBioscience TechnologyThese, too, showed clumps of RanGAP and C9 RNA stuck just outside nuclei. In more fly and iPSC experiments, Rothstein’s team added an antisense oligonucleotide engineered to cling to C9 RNA—and keep it from clinging to RanGAP. The clogged pores …

Read More

Isis Pharmaceuticals’ Collaboration to Discover and Develop Antisense Drugs … – MarketWatch

Smarter AnalystIsis Pharmaceuticals’ Collaboration to Discover and Develop Antisense Drugs …MarketWatchISIS PHARMACEUTICALS’ FORWARD-LOOKING STATEMENTThis press release includes forward-looking statements regarding Isis’ alliance with AstraZeneca, Isis’ research, development and commercial opportunities in developing antisense drugs to treat …Isis-AstraZeneca Collaboration For Antisense Drugs Gets HSR ClearanceNasdaqall 18 news articles »

Read More

Public Release: 10-Sep-2015 Identified genetic interaction offers possible new … – EurekAlert (press release)

EurekAlert (press release)Public Release: 10-Sep-2015 Identified genetic interaction offers possible new …EurekAlert (press release)According to the UC San Diego team, the next step is to conduct preclinical studies to assess the efficacy and safety of antisense oligonucleotides – strands of synthesized DNA or RNA that can prevent transfer of genetic information – which might …and more »

Read More

Vetr Inc. Downgrades ISIS Pharmaceuticals to Buy (ISIS) – Dakota Financial News

Vetr Inc. Downgrades ISIS Pharmaceuticals to Buy (ISIS)Dakota Financial NewsIsis Pharmaceuticals, Inc. (NASDAQ:ISIS) is a Ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is concentrated to find and develop antisense drugs. The antisense drugs are used to take care of a range of …ISIS Pharmaceuticals Lowered to “Buy” at Vetr Inc. (ISIS)Watch List Newsall 2 news articles »

Read More